

Curriculum Vitae of Jan Hillert (Born Oct 21, 1955, pnr 551021-0296)

A. Professional preparations

1981 Medical Degree, Karolinska Institutet. 1987 Qualified specialist i Neurology
1993 Doctor of Medical Sciences, Thesis: Immunogenetics of Multiple sclerosis
1996- Associate professor of Neurology, Karolinska Institutet

B. Appointments

1995- Consultant in Neurology, Karolinska University Hospital
2000- Director MS-Centrum, Huddinge (Multiple Sclerosis Center)
2000-2009 Chief, Division of Neurology, Huddinge
2001- Professor of Neurology at Karolinska University Hospital, Huddinge
2005- 2010 deputy chair, Department of Clinical Neuroscience
2010- Chair (prefekt), Department of Clinical Neuroscience

C. Commissions of trust

Since 2000, I chair the Swedish MS registry, a national quality registry with longitudinal data on over 13,000 MS patients. President of the Swedish Multiple sclerosis Society 2005-2007. 1995-1998 Scientific secretary in the Swedish Society of Neurology. Associate Editor of Neuroscience Letters 2000-2002. On the editorial Board of J Neuroimmunology since 2000. Regular reviewer of grant applications to the Norwegian Research Council, the Italian MS foundation, the Hertie Foundation (Germany), the Swedish Stroke Foundation, the Rheumatology Association and Research Funds of Karolinska Institutet. Occasional reviewer for the British, Italian and Canadian MS Societies.

D. Clinical Experience

Since 1993 physician and 2000-2012 responsible of the Multiple Sclerosis Center at Karolinska University Hospital at Huddinge, seeing MS out-patients weekly. The Center has approximately 1,400 patients, mostly with MS. JH has taken part in more than one dozen clinical trials in MS, including phases 0, 2, 3 and 4. JH has been certified for EDSS, MSFC and taken part in several training sessions on Good Clinical Practice in the context of trials.

E. Networks in Academia and Industry

Chairing the Nordic MS genetics Network group since 1994 (8 academic units in four countries). Member of the International MS Genetics Consortium since 2007. Scientific academic collaborations with joint publications with all Nordic partners, universities of Oxford, Cambridge, Western Ontario, Cagliari, Rome, Milan, Malaga. Ongoing research support contracts with BiogenIdec Inc, Merck-Serono, Bayer-Schering AG. Previous contracts but ongoing collaboration with AstraZeneca and deCode Genetics. Serving on the International Advisory Boards of BiogenIdec Inc, Novartis and

F. Financial support:

Research bodies:

-Swedish Research Council (K2008-62X-11220-14-3), 700 mSEK/yr 2014-2017
-EU-project (PI) NABINMS (25870193), 0,6SEK/year 2006-2009
-Bibbi och Nils Jensens Stiftelse: 2,7 mSEK/yr 2007-2009
-Swedish Foundation for Strategic Research: total 20 mSEK, 2012-2016. I am one of three PI's

Industry:

BiogenIdec, approx 3 MSEK/yr 2014-15

Health Care:

I am responsible for a laboratory (the "NABlab") which turns around 1,5 mSEK/yr in research related clinical services analyzing antibodies to interferon beta therapy.

G. Graduate student supervision:

I have served as main supervisor for 20 graduate students of which the first graduated in 1998 and the latest in June 2014. Assistant supervisor for 10 graduate students from 1997 to 2014. Presently, I am the main supervisor for 1 graduate students and assistant supervisor for 4 students.

H. Academic reviews and other relevant qualifications

I have served as a reviewer/faculty opponent in for 14 doctoral theses, in the Karolinska Institute (three times), University of Linköping (2001 and 2004), University of Cambridge (2002) University of

Sydney (2004), University of Lund 2005, University of Uppsala (2008), University of Oxford (2006), University of Turku, 2008 and University of Umeå (2006 + 2007), University of Copenhagen 2009. Wennmalms Prize (for best thesis), 1993. Max och Edit Follin's Prize, (150.000 SEK) 1996

I. Publications

I have authored and co-authored 290 original scientific papers within the field of Neurology, mostly on multiple sclerosis but also on stroke, headache, or basic science. My foremost research objectives remain epidemiology of MS. Over 10,000 citations, current H-index is 51.

10: Selected publications:

1. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallström E, Khademi M, Oturai A, Ryder LP, Saarela J, Harbo HF, Celius EG, Salter H, Olsson T, Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. *Nat Genet.* 2007 Sep;39(9):1108-13. Epub 2007 Jul 29 PMID: 17660816
2. International Multiple Sclerosis Genetics Consortium (IMSGC). Refining genetic associations in multiple sclerosis. *Lancet Neurol.* 2008 Jul;7(7):567-9. PMID: 18565446
3. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J, Link J, Lundström W, Greiner E, Dossa Sadovnick A, Goossens D, Broeckhoven CV, Del-Favero J, Ebers GC, Oostra BA, van Duijn CM, Hintzen RQ. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. *Nat Genet.* 2008 Nov 9. [Epub ahead of print]
4. Brynedal B, Bomfim IL, Olsson T, Duvefelt K, Hillert J. Differential expression, and genetic association, of CD58 in Swedish multiple sclerosis patients. *Proc Natl Acad Sci U S A.* 2009 Jun 9;106(23):E58; author reply E59. Epub 2009 Jun 2. PubMed PMID: 19497873; PubMed Central PMCID: PMC2695099
5. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):387-401. Epub 2010 Jan 20. PMID: 20089952
6. International Multiple Sclerosis Genetics Consortium (IMSGC), Booth DR, Heard RN, Stewart GJ, Cox M, Scott RJ, Lechner-Scott J, Goris A, Dobosi R, Dubois B, Saarela J, Leppä V, Peltonen L, Pirttilä T, Cournu-Rebeix I, Fontaine B, Bergamaschi L, D'Alfonso S, Leone M, Lorentzen AR, Harbo HF, Celius EG, Spurkland A, Link J, Kockum I, Olsson T, Hillert J, Ban M, Baker A, Kempainen A, Sawcer S, Compston A, Robertson NP, De Jager PL, Hafler DA, Barcellos LF, Ivinson AJ, McCauley JL, Pericak-Vance MA, Oksenberg JR, Hauser SL, Sexton D, Haines J. Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. *Nat Genet.* 2010 Jun;42(6):469-70; author reply 470 1. No abstract available. PMID: 20502484
7. Link J, Lorentzen AR, Kockum I, Duvefelt K, Lie BA, Celius EG, Harbo HF, Hillert J, Brynedal B. Two HLA class I genes independently associated with multiple sclerosis. *J Neuroimmunol.* 2010 Jul 31
8. Lundström W, Greiner E, Lundmark F, Westerlind H, Smestad C, Lorentzen AR, Kockum I, Link J, Brynedal B, Celius EG, Harbo HF, Masterman T, Hillert J. No influence on disease progression of non-HLA susceptibility genes in MS. *J Neuroimmunol.* 2011 Aug 15;237(1-2):98-100. Epub 2011 Jul 13. PMID:21742385
9. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature.* 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251. PMID:21833088
10. Lundström W, Highfill S, Walsh ST, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mackall CL. Soluble IL7R α potentiates IL-7 bioactivity and promotes autoimmunity. *Proc Natl Acad Sci U S A.* 2013 May 7;110(19):E1761-70. doi: 10.1073/pnas.1222303110. Epub 2013 Apr 22.